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http://dx.doi.org/10.1016/j.ccell.2015.04.009SUMMARYTransforming growth factor-b (TGF-b) regulates the expression of genes supporting breast cancer cells in
bone, but little is known about prostate cancer bone metastases and TGF-b. Our study reveals that the
TGFBR1 inhibitor SD208 effectively reduces prostate cancer bone metastases. TGF-b upregulates in pros-
tate cancer cells a set of genes associated with cancer aggressiveness and bone metastases, and the
most upregulated gene was PMEPA1. In patients, PMEPA1 expression decreased in metastatic prostate
cancer and low Pmepa1 correlated with decreased metastasis-free survival. Only membrane-anchored iso-
forms of PMEPA1 interacted with R-SMADs and ubiquitin ligases, blocking TGF-b signaling independently of
the proteasome. Interrupting this negative feedback loop by PMEPA1 knockdown increased prometastatic
gene expression and bone metastases in a mouse prostate cancer model.INTRODUCTION
Prostate cancer (PCa) is one of the most frequently diagnosed
cancers in men and can be an indolent malignancy. However,
in advanced disease, most PCa patients will have bonemetasta-
ses that are associated with hypercalcemia, intractable pain,
fracture, or nerve compression syndrome, causing significant
morbidity. Despite of current US Food and Drug Administra-
tion-approved treatments, bone metastases from PCa remain
incurable and further research is needed to understand the
mechanisms of bone metastases. Recent evidence indicates
that transforming growth factor-b (TGF-b) supports the develop-
ment of PCa bone metastases (Hu et al., 2012; Wan et al., 2012).
TGF-b plays a crucial role in regulating cell proliferation and
differentiation. The TGF-b signaling pathway controls manySignificance
Our preclinical data reveal that in prostate cancer, TGF-b contro
that seen in melanoma and breast cancer, supporting the use
bone, which is an abundant source of TGF-b. PMEPA1 was t
where knocking it down increased bone metastases. The ident
feedback regulator of TGF-b signaling suggests that PMEPA1
b-rich sites and predictor of metastasis-free survival. Enhancin
ment strategy against prostate cancer bone metastases.normal physiological processes, including embryogenesis,
immune responses, and bone remodeling (Mohammad et al.,
2009). TGF-b has a complex and sometimes paradoxical role
in cancer: in early stages, it inhibits cell growth and is a tumor
suppressor, while in later stages, TGF-b promotes invasion
and metastasis, in particular metastasis to bone (Pickup et al.,
2013). Cancer cells in bone disrupt the bone remodeling process
by altering bone resorption and bone formation. In turn, the bone
microenvironment supports cancer cell growth and survival via
osteoblast-produced growth factors embedded in the mineral
bone matrix and released during osteoclastic bone resorption
(Weilbaecher et al., 2011). TGF-b is one of the most abundant
growth factors in bone and is released during osteoclastic
bone resorption. TGF-b signaling is activated in bone metasta-
ses samples from breast cancer (BCa) patients (Kang et al.,ls the expression of a prometastatic gene program similar to
of TGF-b inhibitors to treat prostate cancer metastases to
he gene most increased by TGF-b in prostate cancer cells,
ification of PMEPA1 as a major target of TGF-b and negative
might be a useful prognostic marker of metastases to TGF-
gmembrane-bound PMEPA1 activity could be used as treat-
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2005), and preclinical models have confirmed that bone resorp-
tion increases TGF-b signaling in BCa cells in bone (Korpal et al.,
2009).
The canonical TGF-b signaling pathway uses receptor-
activated SMAD (R-SMAD) proteins 2 and 3, which form com-
plexes in the nucleus with DNA-binding co-factors such as
SP1 and with transcriptional coactivators or corepressors to
regulate gene expression. TGF-b signaling can be turned off by
inhibitors such as HECT type E3 ubiquitin ligases, including
NEDD4, AIP4, and SMURF2, in a proteasome-dependent or in-
dependent manner (Zhang et al., 2001; Lallemand et al., 2005;
Tang et al., 2011). In BCa bone metastases, TGF-b controls
the expression of multiple genes, including CXCR4, MMP1,
IL11, JAG1, or PTHRP, that promote bone metastases (Yin
et al., 1999; Kang et al., 2003, 2005; Sethi et al., 2011). In BCa
and melanoma models, TGF-b signaling is essential for the
formation of bone metastases (Yin et al., 1999; Javelaud et al.,
2007), and it has been well established that anti-TGF-b therapies
significantly reduce the development and progression of the
associated bone metastases in mice (Jua´rez and Guise, 2011).
Recent studies showed that inhibition of TGF-b signaling in
PCa cells inhibits the development of bone metastases (Hu
et al., 2012; Wan et al., 2012), but the underlying molecular
mechanisms involved have not been determined. Characterizing
the role of TGF-b-regulated genes associated with PCa bone
metastases could identify therapeutic targets and diagnostic
markers. Therefore, in this study, we sought to characterize the
role of TGF-b signaling and TGF-b-regulated genes on the devel-
opment of bone metastases of PCa.
RESULTS
The TGFBR1 Inhibitor SD208 Inhibits Osteolytic Bone
Metastases from PCa Cells in Mice
SD208 is a small-molecule inhibitor of the kinase activity of
TGFBR1 (half maximal effective concentration = 48 nM) (Uhl
et al., 2004), we tested its efficacy on human PCa cells, PC-3,
in vitro and in vivo in a murine model of bone metastasis.
In vitro treatment of PC-3 cells with SD208 abrogated SMAD2
phosphorylation induced by TGF-b (Figure 1A). TGF-b also
increased the expression of bone-metastatic genes PTHRP,
IL11, and CTGF in PC-3 cells, while SD208 prevented the
increase of all three mRNAs (Figure 1B). The effects of SD208
were not cytotoxic as assessed by MTT assay of proliferation
of PC-3 cells in the presence or absence of TGF-b (Figure 1C).
To test the efficacy of SD208 in vivo, we used a mouse model
of bone metastases in which PC-3 cells are inoculated into the
left cardiac ventricle of male nudemice. First, we tested the effi-
cacy of a treatment regimen with SD208 (50 mg/kg/day) being
administered starting on day 26 when osteolysis was first de-
tected by X-ray. After 4 weeks of treatment, SD208 significantly
decreased area of osteolysis measured on radiographs by 47%
when compared to vehicle-treated mice (8.9 ± 3.6 versus 16.7 ±
4.3 mm2, respectively) (Figure 1D). However, SD208 did not
improve mouse survival when compared to controls (55 versus
51 days of median survival, respectively) (Figure 1D).
In a prevention protocol where treatment began 3 days
prior to tumor inoculation, SD208 (50 mg/kg/day) signifi-
cantly decreased osteolysis area by 56% when compared to810 Cancer Cell 27, 809–821, June 8, 2015 ª2015 Elsevier Inc.vehicle-treated mice (6.7 ± 3.3 versus 15.3 ± 2.8 mm2, respec-
tively) after 54 days of treatment (Figure 1E). Furthermore,
SD208 significantly increased mouse survival compared to
vehicle-treated mice (57 versus 69 days of median survival
for vehicle- and SD208-treated mice) (Figure 1E). Histomorpho-
metric analysis confirmed that SD208 significantly decreased
the tumor burden in bones (Figure 1F). There were no differ-
ences in total bone area when mice received SD208 (Figure 1F),
which may be due to the fact that the bones were harvested at
different times, since we were measuring mouse survival. Over-
all, our data show that the TGF-b signaling inhibitor SD208
significantly decreased the progression of PC-3 osteolytic
metastases.
Identification of TGF-b Target Genes in PCa Cells
To identify genes regulated by TGF-b in PCa cells, we compared
PC-3 cells cultured with or without TGF-b using Affymetrix gene
chips HU-133A, which can detect 18,100 different transcripts of
14,500 genes. 271 different genes were significantly upregulated
(>1.5-fold increase, p < 0.05) and 67 were significantly downre-
gulated (<1.5 fold decrease, p < 0.05), representing 2.33%
of the genes analyzed (Tables 1, S1, and S2). The results of
this microarray were validated by measuring mRNA levels of
selected genes using qRT-PCR to confirm that TGF-b increases
the expression of Pmepa1, Pthrp, Ctgf, Mmp13, Adam19,
Thbs1, Nedd9, Dkk1, Col1a1, and Vegfa mRNAs (Figures S1
and 2A). A survey of the current literature indicated that many
of the upregulated genes have been linked to cancer and metas-
tases (Table 1). For example, Nedd9,Mmp13, and Upa increase
cell invasion; Itgav increases the homing and adhesion of cancer
cells to bone; Vegfa, Ctgf, and Mmp13 support angiogenesis;
andPthrp,Adam19, andCtgf increase osteolysis (Table 1). Over-
all, this microarray shows that TGF-b increases the expression of
genes in PCa cells that regulate multiple steps of the metastatic
cascade to bone.
The most highly upregulated gene, Pmepa1 (prostate
transmembrane protein androgen induced-1), was increased
23.2-fold by TGF-b in the microarray (Tables 1 and S1), and
qRT-PCR confirmed that TGF-b quickly and durably increased
Pmepa1 mRNA in PC-3 cells (Figure 2A). The PMEPA1 gene
encodes three protein isoforms: a and b contain a type I trans-
membrane domain at the N terminus and localize in the Golgi
apparatus, while isoform c lacks this transmembrane domain
and is cytosolic (Xu et al., 2003) (Figure 2B). To determine which
isoforms are expressed in cancer cells, we cloned the different
PMEPA1 isoforms with a V5 epitope tag at the C terminus.
Each isoform was expressed in COS-7 cells and lysates
analyzed in parallel with different cancer cell lines. In the absence
of TGF-b, only A549 lung cancer cells express detectable
quantities of PMEPA1c (Figure 2C). In the presence of TGF-b,
all prostate (PC-3 and DU145), breast (MDA-MB-231), and lung
(A549) cancer cells tested expressed both membrane-bound
PMEPA1a and cytosolic PMEPA1c (Figure 2C). The isoform b
of PMEPA1 was not detected. Despite activation of TGF-b
signaling as shown by phosphorylated Smad3, HepG2 cells
did not express a detectable amount of any PMEPA1 isoform
(Figure 2C). DNA methylation can prevent induction of PMEPA1
gene by androgens (Sharad et al., 2014). Thus, we cultured
HepG2 with the methyltransferase inhibitors 5-azacytidine or
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Figure 1. SD208 Inhibits TGF-b Signaling in PC-3 Cells In Vitro and Reduces the Development of Bone Metastases from PC-3 in Mice
(A) Western blot analysis of SMAD2 phosphorylation in PC-3 cells pre-treated ±SD208 (1 mM, 1 hr) and further cultured with TGF-b (5 ng/ml, 30–60 min)
before lysis.
(B) Pthrp, Il11, and Ctgf mRNA measured by qRT-PCR in PC-3 cells cultured ±TGF-b (5 ng/ml) and ±SD208 (1 mM) for 24 hr (n = 3).
(C) Growth of PC-3 cells cultured in the presence or absence of TGF-b (5 ng/ml) and SD208 (1 mM) assessed by MTT assay (n = 6).
(D–F)Nudemice inoculatedwith PC-3 cells received SD208 (50mg/kg/day) or its vehicle (D) in a therapeuticmanner (starting on day 26) or (E and F) in a preventive
manner (starting 3 days before cell inoculation) (n = 11 to 14 mice per group). (D and E) Upper: representative radiographs (arrows indicate osteolytic lesions).
Lower: quantification of the osteolysis area on radiographs and Kaplan-Meyer analysis of mouse survival with a log-rank (Mantel-Cox) test. (F) Upper: repre-
sentative H&E-stained sections of femurs (T, tumor; BM, bone marrow). Lower: histomorphometric analysis of tumor burden and bone areas.
Results are expressed as the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, and ns indicates not significant (two-way ANOVA with Bonferroni post-test).
yp < 0.05 (Student’s t test).5-aza-2-deoxycytidine, which restored expression of PMEPA1a
and c in the presence of TGF-b (Figure 2D). The results indicate
that TGF-b induces the expression of PMEPA1a and c in multiple
cancer cell lines and that PMEPA1 expression can be epigenet-
ically regulated by methylation.
Low Expression of PMEPA1 Is Associated with
Metastases and Decreased Survival
The role of PMEPA1 in PCa and bone metastases has not been
determined. To investigate the clinical significance ofPMEPA1 in
cancer, we compared PMEPA1 expression between normal
tissue and primary tumors usingOncomine.PMEPA1 expression
was significantly increased in the primary tumor of patients with
PCa in multiple independent studies (Figures 3A and S2A). Simi-
larly, PMEPA1 expression was increased in the primary tumor ofbreast and lung cancer patients when compared to normal tissue
(Figures 3B, 3C, S2B, and S2C). We used the Yu dataset to
compare PMEPA1 expression at different stages of PCa pro-
gression (Chandran et al., 2007). When compared to prostate
tissue from healthy donors, Pmepa1 mRNA was significantly
increased in the primary tumor as well as in normal tissue adja-
cent to the tumor that can contain higher levels of TGF-b (Fig-
ure 3D). However, in distant non-osseous metastases, PMEPA1
expression was unchanged when compared to normal prostate
and thus was significantly decreased compared to primary
tumors (Figure 3D). To compare PMEPA1 expression between
different metastatic sites, we used the Zhang datasets of BCa
metastases (Zhang et al., 2009). PMEPA1 expression tended
to be higher in bone metastases compared to all other sites of
metastases and was significantly higher than in brain and lungCancer Cell 27, 809–821, June 8, 2015 ª2015 Elsevier Inc. 811
Table 1. Representative Genes Upregulated by TGF-b in PC-3 PCa Cells and Associated with Cancer and Bone Biology, Selected from
Tables S1 and S2
Gene Symbol Gene Name Fold Change p Value Association with Cancer Reference
PMEPA1 prostate transmembrane
protein, androgen induced 1
23.15 0.029 inhibits TGF-b and AR signaling Li et al., 2008;
Watanabe et al., 2010
IGFBP5 insulin-like growth factor
binding protein-5
11.52 0.009 accelerates progression to
androgen independence
Miyake et al., 2000
COL1A1 collagen type 1 a1 4.05 0.038 most abundant protein in the
bone matrix and expressed by
cancer cells homing to bone
Koeneman et al., 1999
NEDD9 neural precursor cell
expressed, developmentally
downregulated 9, HEF1
4.04 0.045 promotes invasion and epithelial-
mesenchymal transition
Morimoto et al., 2014
THBS1 thrombospondin 1 3.81 0.015 activator of TGF-b Crawford et al., 1998
MMP13 matrix metallopeptidase
13 (collagenase 3)
3.49 0.034 supports cancer cell invasion and
tumor angiogenesis and increases
bone metastases
Kudo et al., 2012;
Shah et al., 2012
PTHRP parathyroid hormone-related
protein
3.31 0.040 increases RANKL/OPG ratio and
bone metastases
Yin et al., 1999
ID1 inhibitor of differentiation 1,
inhibitor of DNA binding 1
3.09 0.039 increases prostate cell survival
and proliferation
Schmidt et al., 2010;
Stankic et al., 2013
CTGF connective tissue growth
factor, CCN2
2.93 0.032 increases angiogenesis,
osteoclastogenesis, and
bone metastases
Kang et al., 2003;
Shimo et al., 2006
ADAM19 ADAM metallopeptidase
domain 19
2.73 0.043 solubilizes pro-osteoclastic
RANKL
Chesneau et al., 2003
ITGAV integrin aV (vitronectin receptor) 2.72 0.022 increases homing of cancer cells
to bone
Pe´cheur et al., 2002
VEGFA vascular endothelial growth
factor A
2.29 0.032 increases angiogenesis Roberts et al., 2013
UPA urokinase-type plasminogen
activator
1.81 0.030 pro-invasive protease and tumor
marker
Crippa, 2007
DKK1 Dickkopf 1 homolog 1.52 0.0001 inhibits bone formation and
increases osteolytic metastases
Clines et al., 2007;
Hall et al., 2010
See also Figure S1.metastases in datasets GSE14017 and GSE14018, respectively
(Figure 3E).
We used the PROGgene database to determine the prog-
nostic value of PMEPA1 expression in primary tumors (Gos-
wami and Nakshatri, 2013). The Gulzar dataset (Gulzar et al.,
2013) suggests that PCa recurrence is higher in patients with
low PMEPA1 expression, compared to those with high
PMEPA1 (Figure 3F). Despite the separation between the pop-
ulations after 2 years, the difference was not significant, which
could be due to the small number of patients (n = 67). In the
absence of other available PCa cohorts, we analyzed PMEPA1
in BCa cohorts. The Loi dataset revealed that BCa patients with
lower Pmepa1 mRNA had a significantly earlier recurrence (Fig-
ure 3G) (Loi et al., 2007). Lower expression of PMEPA1 was
also significantly associated with decreased time to metastases
and decreased survival for BCa patients in the Ivishna and
Miller datasets, respectively (Figures 3H and 3I) (Miller et al.,
2005; Ivshina et al., 2006). These findings show clinical signifi-
cance for PMEPA1 in cancer and validate the need to further
understand the regulation of PMEPA1 expression and its
function.812 Cancer Cell 27, 809–821, June 8, 2015 ª2015 Elsevier Inc.TGF-b Activates PMEPA1 Promoter and Increases
PMEPA1 Transcription
To characterize how TGF-b regulates PMEPA1 expression, we
measured Pmepa1 mRNA using qRT-PCR. The transcription in-
hibitor, actinomycin D, abrogated TGF-b-induction of Pmepa1,
while the translation inhibitor, cycloheximide, did not prevent
thePmepa1 increase, suggesting that TGF-b increases PMEPA1
transcription without requiring de novo protein synthesis (Fig-
ure 4A). The TGFBR1 inhibitor SD208 completely prevented
Pmepa1 induction by TGF-b, while inhibitors of p38, JNK, or
MEK kinase had no effect (Figures 4A and 4B). This suggests
that the non-canonical TGF-b signaling pathway does not regu-
late PMEPA1 transcription, which is likely to be regulated by the
SMAD canonical pathway.
To identify the region of PMEPA1 promoter that is activated
and the TGF-b response elements within it, we cloned 3.7 kb
of the human PMEPA1 promoter, from nucleotides 3,699
to +39, relative the transcription start site (NM_020182) into a
pGL3 luciferase reporter plasmid. TGF-b significantly increased
the activity of the PMEPA1 promoter in the TGF-b-responsive
PC-3 (PCa), A549 (lung cancer), and HepG2 (hepatocarcinoma)
A B
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Figure 2. TGF-b Increases the Expression of Membrane-Bound and Cytosolic PMEPA1 in Cancer Cells
(A) Levels of Pmepa1 mRNA assessed in PC-3 cells treated with TGF-b (5 ng/ml). Results are expressed as the mean ± SEM.**p < 0.01 and ***p < 0.001 using
a onw-way ANOVA with Bonferroni post-test.
(B) Schematization of PMEPA1 isoforms.
(C) Western blot analysis of PMEPA1 expression and SMAD3 phosphorylation in prostate (PC-3, DU-145), breast (MDA-MB-231), and lung (A549) cancer cells
and hepatocarcinoma cells (HepG2) treated ±TGF-b (5 ng/ml, 24 hr). Lysates of COS-7 cells transfected to express specific isoforms of PMEPA1 protein were
used as a standard.
(D) PMEPA1 expression in HepG2 cells treated ±TGF-b (5 ng/ml, 24 hr) after culture ±5-azacytidine or 5-aza-2-deoxycytidine (10 mM, 12 days).cells (Figure 4C). The TGFBR1 inhibitor, SD208, prevented
promoter activation by TGF-b (Figure 4C). To confirm the role
of SMAD proteins, we tested the effect of ectopic expression
of SMAD2, 3, 4, or 7 on the PMEPA1 promoter in A549 cells.
Overexpression of SMAD7 significantly decreased PMEPA1
promoter activity induced by TGF-b (Figure 4D). SMAD2 or 4
alone or combined had no effect on TGF-b-induced activity of
the PMEPA1 promoter (Figure 4E). However, overexpression of
SMAD3 significantly increased PMEPA1 promoter activity in
the presence or absence of TGF-b, and the activity of the
promoter was maximal when SMAD3 and 4 were both overex-
pressed (Figure 4E). This result shows that TGF-b-induced
activity of the 3.7-kb PMEPA1 promoter fragment is mediated
by SMAD3 and not SMAD2.
We found five different SMAD3/4 binding elements (SBE),
50-CAGACA-30 (Dennler et al., 1998), on the minus and plus
strands, at positions 717, 2,008, 2,306, 2,629, and
3,284. However, inactivating mutations of any single SBE or
all five SBEs did not affect PMEPA1 promoter activity (Figure 4F).
Deletion analysis of the PMEPA1 promoter to identify TGF-
b-response regions indicated that deletions upstream of
nucleotide538 or downstream of nucleotide492 significantly
decreased TGF-b-induced promoter activity (Figure 4G). The
smallest fragment that had a TGF-b activation similar to the full
fragment is a 1.5-kb fragment (1,467/+39) (Figure 4G). Analysisof this sequence indicated the presence of multiple putative sites
for the transcription factor SP1 within GC-rich regions (69% and
79%GC; Figure S3) where SMADs interacting with SP1 can bind
to DNA (Shi and Massague´, 2003).
Membrane-Bound PMEPA1 Inhibits TGF-b/SMAD
Signaling via HECT E3 Ubiquitin Ligases
PMEPA1 controls negative feedback loops in androgen recep-
tor (AR) and TGF-b signaling (Xu et al., 2003; Watanabe et al.,
2010). Therefore, we studied how the different PMEPA1 iso-
forms affect TGF-b signaling in cancer cells. Specific isoforms
of PMEPA1 were expressed in HepG2 cells that lack endoge-
nous PMEPA1, and TGF-b signaling was monitored with a
synthetic promoter (CAGA)9 reporter in a dual-luciferase assay
(Figure 5A). Membrane-bound PMEPA1a and b significantly
decreased promoter activity induced by TGF-b (Figure 5A) in
a dose-dependent manner (Figure S4A). Cytosolic PMEPA1c
had no effect on (CAGA)9 promoter activity induced by TGF-b
(Figure 5A).
To understand how PMEPA1 inhibits TGF-b signaling, we
introduced inactivating mutations in the PPxY domains and the
SMAD interaction motif (SIM) in the C terminus of all PMEPA1
isoforms (Xu et al., 2003; Watanabe et al., 2010) (Figure 2B).
PMEPA1a and b with a mutated SIM did not inhibit (CAGA)9 pro-
moter activity compared to the wild-type proteins (Figure 5A).Cancer Cell 27, 809–821, June 8, 2015 ª2015 Elsevier Inc. 813
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Figure 3. Low Expression of PMEPA1 Is
Associated with Poor Prognosis in Cancer
Patients
(A–C) PMEPA1 expression levels in normal tissue
and primary tumor of prostate (A), breast (B) and
lung (C) cancer patients (Garber et al., 2001;
Vanaja et al., 2003; Ma et al., 2009). Expression
levels are presented as boxplots and were
compared using an unpaired Student’s t test.
(D) PMEPA1 expression in normal prostate and in
samples from PCa patients (GSE6919 dataset).
(E) PMEPA1 expression in bone, brain, lung, and
liver metastases of BCa patients (GSE14017 and
GSE14018 datasets).
(F–I) Kaplan-Meyer analysis of (F) recurrence-free
survival in the Gulzar dataset (GSE40272), (G)
recurrence-free survival in the Loi dataset
(GSE4922), (H) metastasis-free survival in the
Ivshina dataset (GSE6532), and (I) overall survival
in the Miller dataset (GSE3494) based on PMEPA1
expression in the primary tumor of PCa or BCa
patients. Survival analysis was performed using a
log-rank test.
*p < 0.05 and ***p < 0.005 (one-way ANOVA with
Tukey’s post-test). See also Figure S2.Similarly, inactivating mutation of both PPxY domains reversed
TGF-b signaling inhibition. PMEPA1a or b proteins with only
one of the PPxY domains mutated still inhibited TGF-b signaling
when compared to cells transfected to express LacZ (Fig-
ure S4B). PMEPA1c with mutated SIM and PPxY domain had
no effect on TGF-b signaling (Figure 5A). These results indicate
that only membrane-bound PMEPA1 isoforms inhibit TGF-b
signaling via their SIM and PPxY domains.
To explore further how membrane-bound PMEPA1 regulates
TGF-b signaling, we assessed the PMEPA1-SMAD interaction.
COS-7 cells were co-transfected to express a PMEPA1 isoform
and SMAD2 or 3, followed by SMAD immunoprecipitation. Mem-
brane-bound PMEPA1a and b were co-immunoprecipitated
with SMAD2 and 3 (Figure 5B). PMEPA1c that lacks the trans-
membrane domain was not co-immunoprecipitated with either
SMAD2 or 3 (Figure 5B). The lack of interaction between
PMEPA1c and R-SMADs may explain why PMEPA1c does not
inhibit TGF-b signaling (Figure 5A).Next,we tested the interaction
of PMEPA1a with different HECT E3 ubiquitin ligases in COS-7814 Cancer Cell 27, 809–821, June 8, 2015 ª2015 Elsevier Inc.cells. PMEPA1 was initially identified as
a protein interacting with NEDD4-1. We
confirmed that NEDD4-1 is co-immuno-
precipitated with PMEPA1a, which was
prevented by mutated PPxY domains
(Figure 5C). PMEPA1a also interacted via
its PPxY domains with the HECT E3 ubiq-
uitin ligases NEDD4-2, AIP-4, and
SMURF2, negative regulators of TGF-b
signaling (Figure 5C). E3 ubiquitin ligases
bind to SMAD2/3, so we tested whether
PMEPA1 affected this interaction. When
COS-7 cells were co-transfected to
express SMAD2 and SMURF2, SMURF2
co-immunoprecipitating with SMAD2was hardly detectable (Figure 5D). However, expression of
PMEPA1a increased the amount of SMURF2 precipitated with
SMAD2 (Figure 5D). The increased SMAD2-SMURF2 interaction
was prevented by mutated PPxY PMEPA1a, which cannot
interact with SMURF2. Co-expression of PMEPA1c that did not
inhibit TGF-b signaling had little effect on the SMAD2-SMURF2
interaction (Figure 5D).
Different E3 ubiquitin ligases decrease TGF-b signaling by
proteasome-dependent (Zhang et al., 2001) or independent
mechanisms (Lallemand et al., 2005; Tang et al., 2011). Since
the PMEPA1-E3 ubiquitin ligase interaction is critical for
PMEPA1 function, we tested whether it is mediated by the
proteasome using the proteasome inhibitor MG132. PMEPA1a
expression significantly decreased TGF-b signaling (Fig-
ure S4C), but proteasome inhibition by MG132 (confirmed by
accumulation of ubiquitinated proteins, data not shown) did
not prevent the PMEPA1a effect on (CAGA)9 promoter activity
(Figure S4C). MG132 significantly decreased TGF-b signaling
(Figure S4C), so we tested the effect of catalytically inactive
Figure 4. TGF-b Increases the Transcription of PMEPA1 and Activates a 1.5-kb Fragment of the PMEPA1 Promoter Independently of the
Smad Binding Elements
(A) Levels of Pmepa1 mRNA assessed in PC-3 cells treated with TGF-b (5 ng/ml) in the presence or absence of SD208 (1 mM), cycloheximide (1 mM), or
actinomycin D (1 mg/ml) using qRT-PCR (n = 3).
(B) Measure of Pmepa1mRNA in PC-3 cells treated ±TGF-b (5 ng/ml, 24 hr) in the presence or absence of kinase inhibitors specific for p38 (SD282, 1 mM), JNK
(SP6001250, 5 mM), or MEK (PD98059, 25 mM) using RT-qPCR (n = 3).
(C) Transfection of PC-3, A549, and HepG2 cells with a pGL3 plasmid containing a 3.7-kb fragment (3,699/+39) of PMEPA1 promoter. Cells were then
treated ±TGF-b (5 ng/ml) and ±SD208 (1 mM) for 24 hr before measuring dual-luciferase activity normalized using Renilla luciferase (n = 4).
(D) Ectopic expression of SMAD7 in A549 cells transfected with pGL3-hPMEPA1 (3,699/+39) and treated ±TGF-b (5 ng/ml, 24 hr) before measuring
dual-luciferase activity (n = 4).
(E) Ectopic expression of SMAD2, 3, or 4 in A549 cells transfected with pGL3-hPMEPA1 (3,699/+39) and treated ±TGF-b (5 ng/ml, 24 hr) before measuring dual-
luciferase activity (n = 4).
(F) Effect of SBEmutations (represented by X) on the activity of PMEPA1 (3,699/+39) promoter transfected in A549 cells cultured ±TGF-b (5 ng/ml, 24 hr) before
measuring dual-luciferase activity (n = 4).
(G) Activity of fragments of PMEPA1 promoter measured by dual-luciferase assay in A549 cells cultured ±TGF-b (5 ng/ml, 24 hr) (n = 4).
Results are expressed as the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, and ns indicates not significant (two-way ANOVA with Bonferroni
post-test). See also Figure S3.E3 ubiquitin ligases that cannot transfer ubiquitin to their sub-
strates. AIP4(C830A) and SMURF2(C716A) did not reverse
PMEPA1a-induced inhibition of TGF-b signaling (Figure S4D).
Overall, our results demonstrate that only membrane-bound
PMEPA1 inhibits TGF-b signaling by recruiting SMAD2/3 and
HECT E3 ubiquitin ligases, independently of ubiquitination
and proteasome degradation.Knockdown of PMEPA1 Increases TGF-b Signaling in
Cancer Cells
To assess the role of endogenous PMEPA1 in cancer cells, we
knocked down all Pmepa1 isoforms using two small interfering
RNAs (siRNAs). Transfection of these siRNAs, individually or
pooled, prevented the induction of detectable PMEPA1 pro-
tein by TGF-b (Figure 6A). We tested the effect of PMEPA1Cancer Cell 27, 809–821, June 8, 2015 ª2015 Elsevier Inc. 815
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Figure 5. Only Membrane-Bound PMEPA1
Inhibits TGF-b Signaling Pathway by
Interacting with SMAD2/3 and HECT
E3 Ubiquitin Ligases
(A) (CAGA)9 promoter activity in HepG2 trans-
fected to ectopically express PMEPA1 isoforms
with or without mutations in the SIM and PPxY
domains and cultured ±TGF-b (5 ng/ml, 24 hr).
Results are expressed as the mean ± SEM (n = 4).
****p < 0.0001 (two-way ANOVA with Bonferroni
post-test).
(B) COS-7 cells were transfected with the indi-
cated constructs and subjected to anti-FLAG or T7
immunoprecipitation before western blot analysis
of whole-cell lysate (WCL) and immunoprecipi-
tated fractions (IP).
(C) Transfection of COS-7 cells to express the
indicated constructs before immunoprecipitation
with an anti-V5 antibody and immunoblot analysis.
(D) COS-7 cells were transfected to express the
indicated construct before immunoprecipitation
with an anti-T7 antibody and western blot.
See also Figure S4.knockdown on TGF-b signaling. In PC-3 cells, Pmepa1 siRNAa
decreased SMAD2 phosphorylation compared to controls (Fig-
ure 6B). The Pmepa1 siRNAhad no effect on total SMAD2protein
measured by western blot (Figure 6B), confirming that PMEPA1
inhibition of TGF-b signaling is independent of protein degrada-
tion. Similarly, siPmepa1 increased SMAD2 phosphorylation
without changing total SMAD2 protein in other prostate
(DU145), breast (MDA-MB-231), and lung (A549) cancer cells
(Figure S5A). In HepG2 cells that do not express PMEPA1,
siPmepa1 hadnoeffect onSMAD2phosphorylation (FigureS5A).
We also analyzed the nuclear translocation of SMAD2. After
TGF-b treatment, phosphorylated SMAD2 was not detected in
the non-nuclear fraction regardless of the siRNA transfected (Fig-
ure 6C). In the nuclear fraction, knockdownofPMEPA1 increased
the amount of phosphorylated SMAD2 as well as prolonged the
retention of SMAD2 in the nucleus for up to 2 hr (Figures 6C
and S5B). We measured the mRNAs of TGF-b-regulated genes.
In TGF-b-treated PC-3 cells, PMEPA1 knockdown significantly
increased Il11,Mmp13, and Adam19mRNA (Figure 6D).
PMEPA1was previously shown to regulate cancer cell growth,
either by inhibiting PCa cell proliferation or by preventing TGF-
b-induced growth arrest via p27 and p21, depending on the
study (Xu et al., 2003; Li et al., 2008). We tested the effect of
siPmepa1 on the cell-cycle inhibitors p21 and p27 and of the
cell-cycle regulator CYCLIN D1 in PC-3 and DU145 cells as
well as in E7 and RWPE-1 prostate epithelial cells. Although
siPmepa1 increased p21 in PC-3 and decreased p21 and p27
in DU145, PMEPA1 knockdown had little effect on CYCLIN D1
(Figure S5E). In prostate epithelial cells, PMEPA1 knockdown
had no effect on p21, p27, or CYCLIN D1 expression (Fig-
ure S5E). PMEPA1 knockdown in the presence or absence of
TGF-b did not markedly affect the cell-cycle distribution or the
growth of PC3, DU145, E7, or RWPE-1 cells (Figures S5F and
S5G). These results demonstrate that PMEPA1 knockdown
increases TGF-b signaling and the expression of pro-metastatic
gene but does not affect the growth of PCa cells.816 Cancer Cell 27, 809–821, June 8, 2015 ª2015 Elsevier Inc.PMEPA1 Knockdown Increases PC-3 Bone Metastases
in Mice
To test the role of PMEPA1 in bone metastases, PC-3 cells were
stably transfectedwith plasmids expressing either a small hairpin
RNA (shRNA) control or one knocking down all of the variants of
Pmepa1. Single-cell clones with knockdown of PMEPA1 were
selected and transfection stability tested by culturing the cells
for 70 days in the absence of antibiotic. Two clones (shPmepa1
#5C3 and #1A1) with a >75% decrease of Pmepa1 mRNA
compared to untransfected parental PC-3 cells (data not shown)
and undetectable levels of PMEPA1 protein in the presence of
TGF-b were selected (Figure 6E). We also selected two PC-3
clones expressing shRNAcontrol (shCtrl #5C1 and #3A1) that ex-
pressed levels of PMEPA1 protein similar to parental PC-3 cells
when cultured with TGF-b (Figure 6E). We also compared the
growth of the different PC-3 clones using an MTT assay over
5 days. There were no differences in the proliferation between
the parental PC-3 cells and the shCtrl or shPmepa1 clones in
absence or presence of exogenous TGF-b (Figures S5C and
S5D), similar to the results observed using siRNA.
Male nude mice were inoculated in the left cardiac ventricle
with either a control clone (shCtrl #3A1 or 5C1) or a PMEPA1
knockdown clone (shPmepa1 #5C3 or 1A1). The progression
of osteolytic lesions on radiographs was assessed over 9 weeks.
The area of osteolysis on radiographs was significantly
increased in mice inoculated with the PC-3 shPmepa1 clones
compared to mice inoculated with the PC-3 shCtrl clones (Fig-
ures 6F and 6G). Our results indicate that loss of expression of
PMEPA1 increases PCa bone metastases.
DISCUSSION
Most men with advanced PCa have incurable bone metastases,
amajor source ofmorbidity andmortality. It is therefore critical to
understand the mechanisms of PCa bone metastases to identify
therapeutic targets and develop efficient treatments. Another
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Figure 6. PMEPA1 Knockdown Increases TGF-b Signaling in PC-3 Cells In Vitro and the Development of PC-3 Bone Metastases in Mice
(A) PC-3 cells transfected with a non-targeting siRNA (siControl) or different siRNA against PMEPA1 (siPmepa1 #1 and #2) were treated ±TGF-b (5 ng/ml) before
measuring PMEPA1 expression by western blot.
(B) Immunoblot analysis of SMAD2 phosphorylation in PC-3 cells transfected with siControl or siPmepa1#1+2 (25 mM) and treated with TGF-b (5 ng/ml, 4 hr).
(C) Analysis of SMAD2 phosphorylation in the nuclear and non-nuclear fractions of PC-3 cells transfected with siControl or siPmepa1 (25 mM) and treated with
TGF-b (5 ng/ml).
(D) Il11,Mmp13, and Adam19mRNA levels measured by qRT-PCR in PC-3 cells transfected with siControl (siCtrl) or siPmepa1 (25 mM) and treated with TGF-b
(5 ng/ml). Results are expressed as the mean ± SEM relative mRNA level (n = 3). *p < 0.05, **p < 0.01, and ***p < 0.001 versus siCtrl (one-way ANOVA with a
Dunnett’s post-test).
(E) Expression of PMEPA1 in parental PC-3 cells or after stable transfection to a non-targeting shRNA (shCtrl) or an shRNA against PMEPA1 (shPmepa1) and
cultured ±TGF-b (5 ng/ml, 24 hr).
(F and G)Nudemice were inoculated in the left cardiac ventricle with PC-3 shCtrl (#3A1 or #5C1) PC-3 shPmepa1 (#5C3 or #1A1) cells and surveyed by X-ray over
time. (F) Representative radiographs (arrows indicate osteolytic lesions). (G) Area of osteolysis measured on radiographs.
Results are expressed as the mean area per mouse ± SEM. **p < 0.01 and ***p < 0.001 compared to shCtrl #3A1 or #5C1 (two-way ANOVA with Bonferroni post-
test). See also Figure S5.critical challenge with PCa is to discriminate aggressive from
indolent PCa, since many patients with low-risk disease are
overtreated.
In this study, we demonstrated that SD208, an inhibitor of
TGFBR1 reduced bone metastases from PC-3 PCa cells in
mice. SD208 was more effective when given as a preventive
therapy, which is consistent with previous reports in melanoma
and glioma models (Uhl et al., 2004; Mohammad et al., 2011).
As a preventive agent, SD208 also improved survival. The results
further demonstrate the potential of SD208 to treat or prevent
bone metastases.
Our results suggest that inhibition of TGF-b signaling impairs
the interactions of PC-3 cells with the bone microenvironment,
since SD208 had no effect on cell growth in vitro. These interac-tions drive a feed-forward ‘‘vicious cycle’’ that fuels tumor
growth in bone as tumor cells stimulate bone destruction and
the release of growth factors, such as TGF-b, into the bone
microenvironment. SD208 decreased TGF-b-regulated genes
such as PTHRP and IL11, which are critical for tumor-associated
osteoclastic bone resorption and are likely responsible for the
anti-bone metastasis activity of the drug (Yin et al., 1999; Kang
et al., 2005). This is consistent with a previous study where
SD208 was only efficient at preventing the growth of 1205Lu
melanoma cells in bone, not in soft tissues (Mohammad et al.,
2011). The microarray and PCR analyses confirmed that TGF-b
increases the expression of multiple pro-osteolytic genes:
PTHRP, IL11, and ADAM19. In addition, TGF-b increased the
expression of genes associated with different steps of theCancer Cell 27, 809–821, June 8, 2015 ª2015 Elsevier Inc. 817
Figure 7. Effect of PMEPA1 Expression on Metastases from PCa
Cancer
High expression of PMEPA1 in primary tumor decreases AR and TGF-b
signaling, preventing progression of disease and increasing patient survival.
Methylation of PMEPA1 promoter leads to decreased PMEPA1 expression.
Lower levels of PMEPA1 increase TGF-b signaling and TGF-b-regulated
pro-metastatic genes, ultimately causing an increase in metastases and a
decrease in patient survival.bone metastasis cascade such as angiogenesis (VEGFA, CTGF,
and MMP13) or homing to bone (ITGAV) and invasion (UPA,
MMP13, and NEDD9). Interestingly, many of these genes were
also identified in BCa and melanoma studies (Kang et al.,
2003; Dunn et al., 2009; Mohammad et al., 2011). Therefore,
TGF-b coordinates the expression of multiple genes that coop-
erate to promote PCa bone metastases.
The genemost increased by TGF-b identified in themicroarray
was PMEPA1 (also known as TMEPAI, STAG1, and N4wwBP4).
In vitro, TGF-b quickly and strongly induced the expression of
PMEPA1 isoforms a and c in different prostate, breast, and
lung cancer cell lines. In samples from PCa patients, PMEPA1
is increased in the primary tumor as well as in the tissue adjacent
to it, which contains high levels of TGF-b (Carstens et al., 2014).
Increased resorption at sites of bone metastases also increases
local TGF-b concentration (Korpal et al., 2009), and we found
that PMEPA1 was also higher in bone metastases compared
to other metastatic sites in samples from BCa patients. The
design of the probes in the microarray did not permit discrimina-
tion between the different variants of Pmepa1 isoform mRNAs.
PMEPA1 regulates negative feedback loops in AR and TGF-b
signaling (Li et al., 2008; Watanabe et al., 2010). We confirmed
that overexpression of PMEPA1 in HepG2 cells decreased
TGF-b signaling. However, unlike the findings of Watanabe
et al. (2010), only the transmembrane PMEPA1 inhibited activa-
tion of the (CAGA)9 TGF-b reporter. The cytosolic PMEPA1c iso-
form had no effect on TGF-b signaling when overexpressed in
HepG2 cells, which could be due to the lack of interaction with
R-SMADs. Despite an intact SIM at its C terminus, PMEPA1c
was not co-immunoprecipitated with SMAD2 or 3, suggesting
that intracellular localization of PMEPA1 is important for its func-
tion. Interaction of PMEPA1 with R-SMADs is critical for the inhi-
bition of TGF-b signaling as exemplified by PMEPA1c and by818 Cancer Cell 27, 809–821, June 8, 2015 ª2015 Elsevier Inc.PMEPA1a with a mutated SIM. Similarly, interaction of PMEPA1
via its PPxY domains with HECT E3 ubiquitin ligase is critical for
its function. The results suggest a model where PMEPA1a and b
act as docking proteins to recruit E3 ubiquitin ligases and
R-SMADs and target them for proteasomal degradation. How-
ever, PMEPA1 function was not linked to ubiquitination, and its
knockdown did not increase SMAD2 levels, indicating that the
inhibition of TGF-b signaling by PMEPA1 is proteasome inde-
pendent. It has previously been reported that SMAD7 inhibits
TGF-b signaling by recruiting the E3 ubiquitin ligase AIP4 and
TGFBR1 but without SMAD7 degradation (Lallemand et al.,
2005). Our results suggest that, similarly, membrane-bound
PMEPA1 recruits E3 ubiquitin ligases and SMAD2 or 3, prevent-
ing their phosphorylation and downregulating TGF-b signaling.
In prostate, breast, and lung cancer cells, TGF-b induced
expression of the cytosolic PMEPA1c and the membrane-bound
PMEPA1a. Knockdown of PMEPA1 increased SMAD2 phos-
phorylation and the expression of TGF-b-regulated genes,
demonstrating that endogenous PMEPA1 is an inhibitor of
TGF-b signaling in multiple cancer cells. Accordingly, stable
knockdown of PMEPA1 in PC-3 prostate cancer cells increased
the development of osteolytic bone metastases in mice, consis-
tent with increased expression of prometastatic genes like IL11,
ADAM19, and MMP13.
To determine ifPMEPA1 expression is of clinical relevance, we
interrogated databases of gene expression in patient samples.
Multiple independent datasets of patient samples indicated
that PMEPA1 expression was increased in the primary tumors
of patients with prostate, breast, or lung cancer. This is consis-
tent with previous results showing that PMEPA1 is highly ex-
pressed by epithelial cells of the prostate gland and in tumor
tissues (Xu et al., 2000). However levels of Pmepa1 mRNA
have also been found to be decreased in PCa of higher grade
(Xu et al., 2003). Considering that gene expression in microar-
ray-based datasets is semiquantitative and that we did not
seek to compare the expression of PMEPA1 between different
stages in the primary tumor, these results should be interpreted
with this caveat in mind. These differences could be explained by
the fact that PMEPA1 is expressed selectively in epithelial cells
and epithelial cell content in tumors is variable.
Our results and other previously published data support that
PMEPA1 is a negative regulator of TGF-b signaling (Watanabe
et al., 2010). Since TGF-b acts as a tumor suppressor in the
early stages of cancer, it is possible that, early on, induction of
PMEPA1 expression by environmental factors (i.e., TGF-b, an-
drogens) decreases TGF-b signaling, shielding cancer cells
from its anticancer properties (Pickup et al., 2013) (Figure 7).
However, our study found no effect of PMEPA1 on the prolifera-
tion of PCa cells or prostatic epithelial cells. Additional experi-
ments are needed to characterize the role of PMEPA1 during
the early stages of cancer development. Even though Pmepa1
levels are increased in the primary tumor, we also found that
expression of PMEPA1 was decreased in distant metastases
of PCa patients when compared to the primary tumor. This result
is consistent with the observation of Xu et al. (2003) and with
a report of loss of expression of PMEPA1 due to accumulated
methylation in PMEPA1 promoter (Sharad et al., 2014). Meth-
yltransferase inhibitors restored TGF-b-inducible expression
of PMEPA1 in HepG2 cells, suggesting that TGF-b response
elements in the PMEPA1 promoter can also be inactivated
by methylation. Thus, decreased expression of PMEPA1 in
metastases could be due to epigenetic silencing. We identified
a 1.5-kb fragment of the human PMEPA1 promoter that is
responsive to TGF-b. Further experiments could analyze the
methylation profile of this promoter in cancer cells with high or
low expression of Pmepa1 and ask whether methylation of the
PMEPA1 promoter predicts patient outcomes.
To test the prognostic value of PMEPA1 expression, we used
the PROGgene database. The only PCa dataset available indi-
cated that low Pmepa1 mRNA in the tumors of PCa patients
was associated with shorter time to relapse. The difference
was not significant, perhaps due to small sample size. BCa
datasets offer greater statistical power. Three different datasets
indicated that low expression of Pmepa1 was significantly asso-
ciated with decreased survival and shorter time to relapse or
metastases. The data are consistent with increased bonemetas-
tases caused by Pmepa1 knockdown.
Our results show that decreased PMEPA1 increases TGF-b
signaling and expression of prometastatic genes, suggesting
a model where decreased PMEPA1 expression suppresses a
negative feedback loop and restores TGF-b signaling (Figure 7).
This allows TGF-b to exert its prometastatic effects as cancer
progresses, consistent with our observation thatPmepa1 knock-
down increases bone metastases and that low expression of
PMEPA1 is associated with bad patient prognosis. PMEPA1
not only inhibits TGF-b signaling but also targets the AR for
degradation (Li et al., 2008). It is possible that the increased
time to relapse for PCa patients with higher expression of
PMEPA1 in the primary tumor is due to decreased AR signaling
(Figure 7). Pmepa1 could distinguish indolent from aggressive
PCa and prevent overtreatment of PCa patients. Loss of expres-
sion of PMEPA1 as cancer progresses would restore AR expres-
sion, whose signaling remains active in a large subset of
metastatic PCa patients, including castration-resistant PCa
(Taylor et al., 2010). Thus, the overall role of PMEPA1 in cancer
likely derives from its regulation of both TGF-b and AR signaling.
However, our experiments were conducted with TGF-b-sensi-
tive PCa cells PC-3 and DU145 that are both AR negative, as
the androgen-sensitive PCa cells like LNCap, VCaP, or MDA-
PCa-2b were not found to be TGF-b responsive (data not
shown). Therefore, it was not possible to test the effect of
PMEPA1 loss of expression on both AR and TGF-b signaling.
Despite that limitation, our results in PC-3 and DU145 have
important implications about the role of increased TGF-b activity
caused by PMEPA1 loss and metastatic progression in patients
with AR-negative PCa.
It was recently reported that Pmepa1 knockdown decreased
the growth of Calu3 lung cancer cells in mice (Vo Nguyen
et al., 2014). Analysis of Pmepa1 expression in lung cancer
patient datasets revealed that low levels of Pmepa1 are associ-
ated with a significantly increased survival or longer time before
recurrence in two different cohorts of patients (Figures S2D and
S2E). The pro- and anti-cancer functions of PMEPA1 are prob-
ably microenvironment and cancer-type dependent.
In conclusion, we have shown that TGF-b signaling in PCa
cells increases the expression of numerous genes associated
with the development of bone metastases and that TGF-b sup-
ports the development of bone metastases from PCa in mice.Consequently anti-TGF-b therapies with agents such as SD208
could be used as treatment or prevention. Our study also re-
vealed how membrane-bound PMEPA1a recruits R-SMADs
and E3 ubiquitin ligases to inhibit TGF-b signaling by a
mechanism independent of the proteasome. Loss of PMEPA1
increased TGF-b signaling and development of bonemetastases
in mice. Importantly, our data are validated by evidence from
human databases showing that low levels or loss of expression
of Pmepa1 is associated with poor clinical outcome and could
be used as a predictor of cancer progression in patients suffering
from breast or prostate cancer.
EXPERIMENTAL PROCEDURES
Animal Studies
All mouse experiments were approved by and performed following the guide-
lines of the Institutional Animal Care and Use Committee at the University of
Virginia (Charlottesville, VA). For the bone metastasis study, 4-week-old athy-
mic male mice (Harlan Sprague-Dawley) were anesthetized and inoculated
into the left cardiac ventricle with 105 cancer cells in 100 ml of PBS. The devel-
opment of bone lesions was surveyed by radiography using a Faxitron MX-20
with digital camera (Faxitron Bioptics). Mice were monitored daily for signs of
discomfort, and were either euthanized all at one time or individually when
presenting signs of distress for survival studies. More information about animal
experiments and their analysis can be found in Supplemental Experimental
Procedures.
Cell Culture, Treatment, and Assays
PC-3 and DU145 human PCa cells, HepG2 human hepatocarcinoma cells,
A549 human lung cancer cells, MDA-MB-231 human BCa cells, RWPE-1
normal epithelial prostatic cells, and COS-7 kidney cells from green monkey
were obtained from the American Type Culture Collection (ATCC). E7 prostate
epithelial cells were generated by Drs. Jerde, Ewald, and Jarrard (Indiana Uni-
versity and University of Wisconsin) and were a kind gift from Dr. Travis Jerde
(Indiana University) (Schwarze et al., 2002). E7 cells were cultured in DMEM/
F12 media supplemented with sodium pyruvate and fetal bovine serum (5%)
and used for MTT cell proliferation, RNA extraction, qRT-PCR, dual-luciferase
assay, immunoprecipitation, and immunoblotting. More information on these
methods including transfection, antibodies, reagents, and plasmids is pro-
vided in Supplemental Experimental Procedures.
Microarray Analysis and Data Mining
Microarray analysis with Affymetrix chips was performed by the University of
Virginia Biomolecular Research Facility. See Supplemental Experimental Pro-
cedures for details.
Expression of PMEPA1 in normal andmalignant samples of prostate, breast,
and lung tissues from patients was queried using the Oncomine database. The
p values presented were extracted directly from the Oncomine analysis, and
the tests have not been repeated manually. To compare PMEPA1 expression
in patient samples, the datasets GSE6919, GSE14017, and GSE14018 were
downloaded from the PubMedGene Expression Omnibus (GEO) and analyzed
by the Center for Computational Biology and Bioinformatics (Indiana Univer-
sity). The prognostic value of Pmepa1 mRNA in the primary tumor of patients
with prostate, breast, or lung cancer was assessed using the PROGgene data-
base (Goswami and Nakshatri, 2013). Relapse-free, metastasis-free, or overall
survival was compared between high and low PMEPA1 expression groups
using median gene expression value as a bifurcating point.
Statistical Analysis
Statistical analysis of themicroarray data was performed using dChip software
and Student’s t test. The significance criterion consisted of (1) p % 0.05, (2)
fold change R 1.5 or % 1.5, and (3) signal differential R Min (100, 103
10%mean signal intensity of absent probe sets). Statistical analyses were per-
formed using GraphPad Prism 5.0 software (GraphPad). Comparisons of two
groups were performed with a non-parametric Mann-Whitney U test, and for
comparisons of three or more groups, we used a one-way ANOVA test, withCancer Cell 27, 809–821, June 8, 2015 ª2015 Elsevier Inc. 819
a Dunnett’s post-test when comparing to a control group or with a Bonferroni
test to compare selected pairs of group. For responses that are affected by
two variables, a two-way ANOVA with a Bonferroni post-test was used. To
compare mouse survival, we used Kaplan-Meier analysis with a log-rank
(Mantel-Cox) test. Analysis of patient survival data was done as described
previously (Goswami and Nakshatri, 2013). Results are expressed as
mean ± SEM, and a p% 0.05 was considered significant.
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